IN2015KN00702A - - Google Patents

Info

Publication number
IN2015KN00702A
IN2015KN00702A IN702KON2015A IN2015KN00702A IN 2015KN00702 A IN2015KN00702 A IN 2015KN00702A IN 702KON2015 A IN702KON2015 A IN 702KON2015A IN 2015KN00702 A IN2015KN00702 A IN 2015KN00702A
Authority
IN
India
Application number
Inventor
Matthew R Lewin
Original Assignee
Ophirex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ophirex Inc filed Critical Ophirex Inc
Publication of IN2015KN00702A publication Critical patent/IN2015KN00702A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN702KON2015 2012-09-10 2015-03-16 IN2015KN00702A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261743705P 2012-09-10 2012-09-10
US201361771750P 2013-03-01 2013-03-01
US201361824087P 2013-05-16 2013-05-16
US201361857032P 2013-07-22 2013-07-22
PCT/US2013/058640 WO2014039920A1 (en) 2012-09-10 2013-09-06 Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade

Publications (1)

Publication Number Publication Date
IN2015KN00702A true IN2015KN00702A (en) 2015-07-17

Family

ID=50237663

Family Applications (1)

Application Number Title Priority Date Filing Date
IN702KON2015 IN2015KN00702A (en) 2012-09-10 2015-03-16

Country Status (8)

Country Link
US (1) US20150224094A1 (en)
EP (1) EP2892521A4 (en)
AU (1) AU2013312240A1 (en)
CA (1) CA2884566A1 (en)
IN (1) IN2015KN00702A (en)
MX (1) MX2015003035A (en)
WO (1) WO2014039920A1 (en)
ZA (1) ZA201501561B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012068161A1 (en) 2010-11-15 2012-05-24 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
EP3083569B1 (en) 2013-12-20 2022-01-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
MA40998A (en) 2014-11-21 2017-09-26 Ophirex Inc THERAPIES AGAINST ENVENIMATION, AS WELL AS ASSOCIATED COMPOSITIONS, SYSTEMS AND PHARMACEUTICAL KITS
CA2990004C (en) 2015-06-19 2024-04-23 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
KR20190005898A (en) * 2016-04-29 2019-01-16 오피렉스, 인크. PLA2 and HMG-COA inhibitors for the treatment of pathological diseases resulting in hemolysis, cerebral edema, and acute renal injury
EP3454855B1 (en) 2016-05-13 2023-12-20 Delnova, Inc. Treating of side-effects resulting from chemodenervation
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20200352923A1 (en) * 2017-11-15 2020-11-12 DelNova, Inc. Treatment of side effects of botulinum therapies
EA202190076A1 (en) 2018-06-19 2021-09-22 Эйджинбайо, Инк. BENZODIAZEPINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATMENT OF COGNITIVE DISORDERS
CN114931551B (en) * 2022-05-11 2023-04-25 四川科瑞德制药股份有限公司 Miku ammonium chloride injection with storage stability at 25 ℃ and preparation method and application thereof
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4060652A (en) * 1976-05-26 1977-11-29 Khromov Borisov Nikolai Vasili Nondepolarizing muscle relaxant
JP3923099B2 (en) * 1995-06-05 2007-05-30 帝人株式会社 Nasal antidote
AU2003298514A1 (en) * 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20030225031A1 (en) * 2002-05-21 2003-12-04 Quay Steven C. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
EP1663203A1 (en) * 2003-09-19 2006-06-07 The Secretary of State for Defence Pharmaceutical compositions for the treatment of organophosphate poisoning
EP1684753A2 (en) * 2003-10-28 2006-08-02 Cornell Research Foundation, Inc. Neuromuscular blocking agents and antagonists thereof

Also Published As

Publication number Publication date
EP2892521A4 (en) 2016-06-29
MX2015003035A (en) 2015-09-21
US20150224094A1 (en) 2015-08-13
WO2014039920A1 (en) 2014-03-13
AU2013312240A1 (en) 2015-03-19
CA2884566A1 (en) 2014-03-13
EP2892521A1 (en) 2015-07-15
ZA201501561B (en) 2016-10-26

Similar Documents

Publication Publication Date Title
BR112014017635A2 (en)
BR112014019107A2 (en)
BR112014018957A2 (en)
BR112014020010A2 (en)
BR112014017625A2 (en)
BR112014017659A2 (en)
BR112014020055A2 (en)
BR112014018848A2 (en)
BR112014019439A2 (en)
BR112014017646A2 (en)
AR092201A1 (en)
BR112014017638A2 (en)
BR112014019538A2 (en)
BR112014017634A2 (en)
BR112014017644A2 (en)
BR112014017647A2 (en)
IN2015KN00702A (en)
BR112014017630A2 (en)
BR112014017652A2 (en)
BR112014017621A2 (en)
BR112014017622A2 (en)
BR112014017627A2 (en)
BR112014017623A2 (en)
BR112014017631A2 (en)
BR112014018751A2 (en)